 Connection
Angus Toland to Biomarkers, Tumor
This is a "connection" page, showing publications Angus Toland has written about Biomarkers, Tumor.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.644 |
|
|
|
-
Gilani A, Willard N, Mulcahy Levy JM, Skaugen J, Toland A. Are PDFGRA Dinucleotide Alterations Definitional for Myxoid Glioneuronal Tumor? Report of PDFRA p. K385L Mutation in a Neonatal High-Grade Glioma. Pediatr Dev Pathol. 2025 Mar-Apr; 28(2):126-132.
Score: 0.582
-
Craig A, G?ney E, Pekmezci M, Bloomer M, Laszik Z, Ohgami RS, Toland A, Vogel H, Forns T, Wang E, Rubenstein J, Wen KW. Utility of PD-1, PD-L1, and IDO-1 Stains in Ocular Extranodal Marginal Zone Lymphoma (MZL) and Diffuse Large B-cell Lymphoma (DLBCL). Appl Immunohistochem Mol Morphol. 2024 Sep 01; 32(8):395-399.
Score: 0.035
-
Raghavan SS, Wang JY, Toland A, Bangs CD, Rieger KE, Novoa RA, Charville GW, Brown RA. Diffuse PRAME expression is highly specific for malignant melanoma in the distinction from clear cell sarcoma. J Cutan Pathol. 2020 Dec; 47(12):1226-1228.
Score: 0.027
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|